Does TARLATAMAB-DLLE Cause Off label use? 111 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 111 reports of Off label use have been filed in association with TARLATAMAB-DLLE (IMDELLTRA (AMG757)). This represents 13.8% of all adverse event reports for TARLATAMAB-DLLE.
111
Reports of Off label use with TARLATAMAB-DLLE
13.8%
of all TARLATAMAB-DLLE reports
5
Deaths
36
Hospitalizations
How Dangerous Is Off label use From TARLATAMAB-DLLE?
Of the 111 reports, 5 (4.5%) resulted in death, 36 (32.4%) required hospitalization, and 6 (5.4%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TARLATAMAB-DLLE. However, 111 reports have been filed with the FAERS database.
What Other Side Effects Does TARLATAMAB-DLLE Cause?
Cytokine release syndrome (274)
Immune effector cell-associated neurotoxicity syndrome (127)
Pyrexia (75)
Small cell lung cancer (66)
Death (45)
Disease progression (34)
Metastases to central nervous system (28)
Decreased appetite (23)
Dysgeusia (22)
Fatigue (22)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which TARLATAMAB-DLLE Alternatives Have Lower Off label use Risk?
TARLATAMAB-DLLE vs TASIGNA
TARLATAMAB-DLLE vs TASIMELTEON
TARLATAMAB-DLLE vs TAVABOROLE
TARLATAMAB-DLLE vs TAXOL
TARLATAMAB-DLLE vs TAXOTERE